Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 841

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 841
---
 a p.v. NIS 0.1 of the Company for an exercise price of about NIS 3; the warrants would be exercisable until September 30, 2020 (hereinafter, the “Series E1 Warrant”). The warrants’ value, USD $173 thousand, was determined according to the Black -Scholesmodel based on the following assumptions:

| Dividend yield for the share (%)           |     |     — |   |
| Expected share price volatility (%)        |     | 67.14 | % |
| Risk-free interest rate (%)                |     |   0.2 | % |
| Share price USD $0.03 (NIS 0.1 p.v.) (USD) |     |  1.00 |   |

On September 30, 2020, 638,708 Series E1 warrants totaling USD $170 thousand expired. 2.645,706 non -marketableSeries E2 Warrants, each of which was exercisable into an ordinary share in the Company, USD$ 0.03 p.v., for an exercise price of USD $1.46, the warrants were exercisable until December 31, 2021 (hereinafter, the “Series E2 Warrant”).

Annex G-33

KADIMASTEM LTD.
NOTES TO FINANCIAL STATEMENTS Note 18: — EQUITY (cont.) The value of the warrants, USD $156 thousand, was determined according to the Black -Scholesmodel based on the following assumptions:

| Dividend yield for the share (%)           |     |     — |   |
| Expected share price volatility (%)        |     | 67.14 | % |
| Risk-free interest rate (%)                |     |   0.2 | % |
| Share price USD $0.03 (NIS 0.1 p.v.) (USD) |     |  1.02 |   |

The issuance of Series E1 warrants and Series E2 warrants was approved by the Company’s Board of Directors on February 13, 2020, the issuance of the shares that would result from the exercise of the warrants was approved for listing by the TASE on March 12, 2020. On August 31, 2021, 67,884 Series E2 warrants were exercised for USD $99 thousand (the exercise price). On December 31, 2021, 577,882 Series E